Cohort profile: Canadian study of prediction of

death, dialysis and interim cardiovascular events

(CanPREDDICT) by Levin, Adeera et al.
Levin et al. BMC Nephrology 2013, 14:121
http://www.biomedcentral.com/1471-2369/14/121STUDY PROTOCOL Open AccessCohort profile: Canadian study of prediction of
death, dialysis and interim cardiovascular events
(CanPREDDICT)
Adeera Levin1*, Claudio Rigatto2, Barrett Brendan3, François Madore4, Norman Muirhead5, Daniel Holmes6,
Catherine M Clase7, Mila Tang6, and Ognjenka Djurdjev8 on behalf of the CanPREDDICT investigatorsAbstract
Background: The Canadian Study of Prediction of Death, Dialysis and Interim Cardiovascular Events (CanPREDDICT)
is a large, prospective, pan-Canadian, cohort study designed to improve our understanding of determinants of renal
and cardiovascular (CV) disease progression in patients with chronic kidney disease (CKD). The primary objective is
to clarify the associations between traditional and newer biomarkers in the prediction of specific renal and CV
events, and of death in patients with CKD managed by nephrologists. This information could then be used to
better understand biological variation in outcomes, to develop clinical prediction models and to inform enrolment
into interventional studies which may lead to novel treatments.
Methods/Designs: Commenced in 2008, 2546 patients have been enrolled with eGFR between 15 and 45 ml/min
1.73m2 from a representative sample in 25 rural, urban, academic and non academic centres across Canada.
Patients are to be followed for an initial 3 years at 6 monthly intervals, and subsequently annually. Traditional
biomarkers include eGFR, urine albumin creatinine ratio (uACR), hemoglobin (Hgb), phosphate and albumin. Newer
biomarkers of interest were selected on the basis of biological relevance to important processes, commercial
availability and assay reproducibility. They include asymmetric dimethylarginine (ADMA), N-terminal pro-brain
natriuretic peptide (NT-pro-BNP), troponin I, cystatin C, high sensitivity C-reactive protein (hsCRP), interleukin-6 (IL6)
and transforming growth factor beta 1 (TGFβ1). Blood and urine samples are collected at baseline, and every 6
monthly, and stored at −80°C. Outcomes of interest include renal replacement therapy, CV events and death, the
latter two of which are adjudicated by an independent panel.
Discussion: The baseline distribution of newer biomarkers does not appear to track to markers of kidney function
and therefore may offer some discriminatory value in predicting future outcomes. The granularity of the data
presented at baseline may foster additional questions.
The value of the cohort as a unique resource to understand outcomes of patients under the care of nephrologists
in a single payer healthcare system cannot be overstated. Systematic collection of demographic, laboratory and
event data should lead to new insights.
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The mean age of the cohort was 68 years, 90% were Caucasian, 62% were male, and 48% had diabetes. Forty
percent of the cohort had eGFR between 30–45 mL/min/1.73m2, 22% had eGFR values below 20 mL/min/1.73m2;
61% had uACR < 30. Serum albumin, hemoglobin, calcium and 25-hydroxyvitamin D (25(OH)D) levels were
progressively lower in the lower eGFR strata, while parathyroid hormone (PTH) levels increased. Cystatin C, ADMA,
NT-proBNP, hsCRP, troponin I and IL-6 were significantly higher in the lower GFR strata, whereas 25(OH)D and
TGFβ1 values were lower at lower GFR. These distributions of each of the newer biomarkers by eGFR and uACR
categories were variable.
Keywords: Chronic kidney disease, Biomarkers, Observational cohort study, Outcomes, Progression, CV diseaseBackground
Chronic kidney disease (CKD), defined as the presence
of persistent reduction in kidney function (i.e. glome-
rular filtration rate (GFR) <60mL/min for more than 3
months) or evidence of chronic kidney damage (e.g. pro-
teinuria), is a growing global health problem. CKD af-
flicts 10-13% of adults in North America, Europe and
Australia [1-5]. There is evidence that the prevalence of
CKD is increasing in parallel with the increasing pre-
valence of hypertension, diabetes and obesity. The diag-
nosis of CKD is important because it is a powerful
risk factor for development of end-stage renal disease
(ESRD), a condition associated with significant patient
morbidity, excessive mortality, and high societal cost re-
lated to provision of dialysis (an expensive therapy)[6].
More recently, CKD, even in the early stages, has been
associated with accelerated cardiovascular (CV) disease
and death [7,8]. For all of these reasons, identification of
patients with CKD, appropriate longitudinal follow-up,
and treatment with therapies to prevent progression, are
major current and future challenges for healthcare sys-
tems worldwide.
The major causes of CKD in developed societies are
hypertension, diabetes, atherosclerotic vascular disease,
and certain glomerular diseases (e.g. IgA nephropathy).
Even within etiological categories, however, there is wide
variation in rates of progression [9-11]: some patients
progress rapidly to ESRD, whereas other patients remain
stable indefinitely with minor reduction in kidney func-
tion. The link between CKD and accelerated CV disease
adds prognostic complexity because some patients with
progressive CKD will succumb to death from CV causes
rather than progress to dialysis. This phenomenon of
competing risks further complicates the ability to predict
specific outcomes in individual patients.
The variable prognosis of CKD is highly problematic
for health systems, health practitioners, and patients
alike. Patients very reasonably want to know what will
happen to their kidneys down the road. Will dialysis be
needed, and when? Uncertainty in prognosis is troubling
for patients, hampers psychosocial adaptation to illness,
and degrades quality of life [12-15]. Health practitionersneed accurate prognostic estimates in order to appropri-
ately counsel CKD patients, plan frequency of follow-up,
and determine optimal timing for procedures required
in preparation for dialysis, such as arteriovenous fistula
creation, or referral for pre-emptive transplantation. From
the health systems perspective, CKD care is expensive, re-
quiring specialized resources and frequent visits. These re-
sources would be optimally directed to those patients at
true risk of progression, and not to those at minimal risk
of adverse outcomes.
Although progress has been made in developing usable
prediction models for risk of dialysis in CKD populations
[16], much less progress has been made in terms of pre-
dicting other important outcomes such as CV disease
and death. Better identification and understanding of the
factors predisposing to these key outcomes in CKD are
needed. In this regard, several newer biomarkers which
reflect biological processes linked to renal and cardiac
disease progression have shown promise in predicting
outcomes in CKD, but have not yet been properly vali-
dated and compared in the context of conventional risk
factors for progression.
The Canadian study of Prediction of Risk and Evolu-
tion to Dialysis, Death and Interim CV events over Time
(CanPREDDICT) was established in 2008 to address these
questions of interest.
Methods/Design
Overarching objectives
CanPREDDICT is a large, prospective, pan-Canadian co-
hort study with the primary objective of describing the
associations between traditional and newer biomarkers
in the prediction of renal and CV events in patients with
CKD managed by nephrologists. This information will
then be used to better understand biological variation in
outcomes, to develop clinical prediction models and to
inform enrolment into interventional studies which may
lead to novel treatments.
Study cohort
CanPREDDICT includes 2546 adult patients recrui-
ted from outpatient nephrology clinics in 25 Canadian
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practice in Canada: rural and urban, university and non-
university affiliated centres are represented. Recruitment
of the cohort was achieved over an 18-month period
between June 2008 and December 2009. Patients were eli-
gible for inclusion in the cohort if they had a baseline
eGFR of 15–45 mL/min/1.73m2. Patients were excluded if
they were unable to provide informed consent, had an
organ transplant, were on immunomodulatory therapy for
active vasculitis or glomerulonephritis, or who had a life
expectancy of less than 1 year (e.g. due to cancer) in the
opinion of their attending nephrologist (Figure 1).Adult CKD patients screened in
25 Canadian outpatient nephrology clinics
n=7665
Adult CKD patients, eGFR 15-45 ml/min,
enrolled in CanPreddict study cohort
n=2544
Baseline data available for analysis
n=2402
6-month follow-up
12-month follow-up
18-month follow-up
24-month follow-up
30-month follow-up
36-month follow-up
Figure 1 Cohort flow diagram.The study protocol was approved by the institutional
review boards of all 25 participating centres, led by the
University of British Columbia and Providence Health
Care Research Institute as the coordinating site; and the
research was conducted in accordance with the Dec-
laration of Helsinki. The study was registered at www.
clinicaltrials.gov (# NCT00826319).
Funding sources
The direct costs of the study are funded by an unres-
tricted educational grant from Janssen-Ortho Inc. The
concept, design and execution of the study, including allExcluded (Total=5121)
1. Ineligible (n=2419)
- eGFR out-of-range n=1385
- Not receiving care for CKD n=  327
- Life expectancy < 12 mo. n=  168
- Organ transplant patients n=  163
- Active Vasculitis n=    39
- Other n=  337
2. Eligible, but not recruited (n=2702)
- Not interested n=  873
- Refused consent n=  763
- Recruitment completed
before they were approached n=1066
Newer biomarker result(s) missing at
baseline (n=142)
- One result missing n=69
- Two or more results missing n=50
- All biomarker results missing n=23
12-month attrition (n=93)
- Withdrawal/patient refusal n=59
- Lost-to-follow-up n=27
- Unable/disease worsening n=  1
- Other n=  6
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driven. Statistical and methodological support is provided
from University of British Columbia and the BC Provincial
Renal Agency. Funding from the Kidney Foundation of
Canada for ancillary studies (Bioimpedance in CKD) has
been received, and other applications for peer-reviewed
funding are pending.
Specific study objectives and outcomes of interest
The main objectives of the CanPREDDICT study are 1)
to examine the role of both traditional risk factors and a
select panel of newer, non-traditional serum and urine
biomarkers, in the progression of kidney and CV disease
in patients with CKD, alone and separately and 2) to de-
velop robust predictive models to discriminate between
high and low risk patients.
The main outcomes of interest in the CanPREDDICT
study include renal endpoints: progression of CKD to
renal replacement therapy (RRT), CV events (both heart
failure and ischemic events) and death.
Definitions of outcomes and adjudication
RRT is defined as need for dialysis initiation or renal
transplantation. Major CV events are defined as fatal or
non-fatal myocardial infarction (MI), defined as chest
pain, dynamic troponin change, cardiogenic shock and
ECG to distinguish ST-elevated MI vs non-ST-elevated
MI), ischemic stroke (defined as an acute focal neuro-
logic deficit of sudden onset attributed to the occlusion
of a cervicoencephalic artery by a thrombus, supported
by CT or MRI results), or need for coronary revascula-
rization (coronary artery bypass graft/percutaneous co-
ronary intervention/percutaneous transluminal coronary
angioplasty supported by procedural note). Congestive
heart failure (CHF) is defined as dyspnea plus 2 of the
following: bibasilar rales, raised jugular venous pressure
or chest x-ray with evidence of interstitial or alveolar
pulmonary edema. A panel of three physicians compri-
sing a nephrologist, a cardiologist, and a neurologist
independently adjudicated all CV outcomes based on
source documentation.
Duration of the study
Follow-up was originally planned for 3 years, with com-
pletion of the main study in December 2012, but has
been extended for an additional 2 years.
Data collection
Demographics, clinical status, medications, as well as
blood and urine samples are collected at baseline and
every 6 months at study visits for the first 3 years. An
abbreviated set of data (events and clinical data only)
will be collected annually during the 2-year extension.In addition to traditional clinical and laboratory risk
factors for cardiac or renal disease progression, a select
panel of newer biomarkers are also being measured: asym-
metric dimethylarginine (ADMA), interleukin-6 (IL-6),
high sensitivity C-reactive protein (hsCRP), cystatin C,
transforming growth factor beta 1 (TGFβ1), troponin I,
and N-terminal pro-brain natriuretic peptide (NT-pro-
BNP). These biomarkers were chosen based on 1) es-
tablished biological importance in disease processes of
interest (inflammation, ischemia, fibrosis, oxidative stress
and vascular health), 2) robust evidence of association
with clinical outcomes, and 3) commercial availability of
assays [17-35]. Importantly, blood and urine samples have
been banked to permit validation of future biomarkers not
considered in the present study, and to permit future ge-
nomic and proteomic studies. All study data are entered
via electronic, web-based case report forms.
Measurement details of the newer biomarkers are de-
scribed in the Additional file 1. Traditional biomarkers
(creatinine, urine albumin-creatinine ratio (uACR), he-
moglobin (Hgb), phosphate etc.,) are all measured in
local accredited laboratories across Canada. Serum cre-
atinine is calibrated to local platforms but traceable to
NIST standards in all laboratories. The calculation of
eGFR used MDRD formula, as is the norm in Canada at
the time of the study start [36].Sample size considerations
The primary considerations for the sample size esti-
mation were: 1) to ensure adequate power to demon-
strate that inclusion of novel biomarkers in predictive
models would enhance discrimination between sub-
jects who will or will not experience outcomes; and
2) a high level of precision when assessing the dis-
criminatory value of the new predictive models that
include biomarkers. A sample size of 2500 would yield es-
timated standard errors of approximately 1%, which would
provide 99% power to demonstrate that the novel bio-
markers would be statistically significant predictors if
the hypothesized increase in discrimination of 5% exis-
ted. Also, this sample size allowed quantification of the
magnitude of the increase with high precision. As des-
cribed in the Additional file 1, we used a simulated bio-
marker behavior, not any specific biomarker to develop
the sample size.Patient follow up
As a longitudinal observational cohort study, clinical
visits every 6 months for the initial 3 years, and then
annually for an additional 2 years are planned. During
the first 12 follow-up months, attrition was low, with
4% of the cohort lost to follow-up (see Figure 1 for
details).
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Clinical and demographic data were obtained at baseline
visits. Data elements include age, sex, race, diabetic sta-
tus, cause of renal disease, and pre-existing comorbidi-
ties including ischemic heart disease (IHD), congestive
heart failure (CHF), cerebrovascular disease, peripheral
arterial disease, chronic lung disease, chronic liver dis-
ease, chronic gastrointestinal disease and previous diag-
nosis of cancers. Blood pressure, height and weight,
routine laboratory testing (near study visit date, maximumTable 1 Baseline characteristics stratified by eGFR level
Variables All eGFR Level
< 20 ml/min
N 2402 533 (22%)
Age (in years) 68.1 (12.7) 66.9 (13.5)
Gender (% Male) 1502 (63%) 311 (58%)
Race (% Caucasian) 2142 (89%) 471 (88%)
Diabetes 1160 (48%) 251 (47%)
Primary Kidney Disease
Diabetic Nephropathy 699 (29%) 167 (31%)
Hypertensive Nephropathy 637 (27%) 124 (23%)
Glomerulonephritis 273 (11%) 75 (14%)
Polycystic Kidney Disease 103 (4%) 29 (5%)
Other 690 (29%) 138 (26%)
eGFR mL/min/1.73m2 27.9 (9.0) 16.8 (2.0)
Albumin g/L 40.4 (4.2) 39.7 (4.5)
Hemoglobin g/L 122 (16) 117 (14)
Cholesterol mmol/L 4.25 (1.17) 4.13 (1.21)
Calcium mmol/L 2.30 (0.14) 2.27 (0.15)
Phosphate mmol/L 1.22 (0.26) 1.37 (0.26)
1,84 Parathyroid Hormone pg/mL 44 (21–69) 76 (46–122)
Bicarbonate mmol/L 25.4 (3.6) 24.1 (4.0)
ACR mg/mmol 16 (3–88) 54 (13–209)
ACR
< 3.4 mg/mmol 632 (27%) 50 (11%)
3.4-33.9 mg/mmol 818 (34%) 137 (30%)
34.0-113.0 mg/mmol 410 (17%) 109 (24%)
> 113.0 mg/mmol 512 (22%) 167 (36%)
Cystatin C ng/mL 1888 (539) 2419 (469)
ADMA μM 0.543 (0.113) 0.557 (0.117)
NT-pro-BNP pg/mL 465 (186–1359) 771 (297–235
CRP mg/L 2.9 (1.2-6.7) 3.4 (1.4-7.3)
TGF β1 pg/mL 19838 (15919–25085) 18343 (14365
IL6 μg/L 4.4 (1.0-7.1) 4.8 (1.0-7.8)
Troponin I > LLD 910 (37%) 244 (44%)
25-hydroxyvitamin D ng/mL 23.9 (16.3-33.4) 21.2 (14.4-30
*LLD: Lower Detection Limit.4 months prior and 2 months after) were also obtained.
Serum, plasma and urine samples are collected for analysis
in a central laboratory at each visit. Patient follow-up con-
tinues after transition to dialysis or transplantation, until
death or lost to follow-up. In addition to the demographic
and clinical data described above, the six pre-specified
newer biomarkers were selected for measurement. As
described above, the selection was done on the basis of
biological relevance, commercial availability of assays, and
published data suggesting prognostic value for heartP value
20-29 ml/min ≥ 30 ml/min
933 (39%) 936 (40%)
68.7 (12.6) 68.3 (12.3) 0.033
569 (61%) 622 (66%) 0.004
834 (89%) 837 (89%) 0.79
480 (51%) 429 (46%) 0.043
291 (31%) 241 (26%) <0.0001
248 (27%) 265 (28%)
104 (11%) 94 (10%)
33 (4%) 41 (4%)
254 (28%) 295 (32%)
24.9 (2.9) 37.2 (5.6) <0.0001
40.4 (4.1) 40.8 (4.3) <0.0001
123 (14) 127 (17) <0.0001
4.28 (1.09) 4.29 (1.23) 0.17
2.30 (0.14) 2.32 (0.14) <0.0001
1.22 (0.22) 1.13 (0.24) <0.0001
41 (31–85) 33 (20–48) <0.0001
25.1 (3.4) 26.6 (3.2) <0.0001
18 (3–87) 7 (2–43) <0.0001
222 (25%) 348 (36%) <0.0001
321 (36%) 347 (36%)
157 (17%) 137 (14%)
198 (22%) 137 (14%)
1957 (424) 1519 (373) <0.0001
0.548 (0.113) 0.529 (0.112) <0.0001
0) 515 (227–1235) 314 (130–940) <0.0001
2.9 (1.1-6.7) 2.7 (1.1-6.1) 0.026
–22865) 19803 (15936–24729) 21043 (16678–26467) <0.0001
4.5 (1.0-7.2) 4.1 (1.0-6.7) <0.0001
360 (38%) 306 (31%) <0.0001
.9) 23.7 (16.0-33.5) 26.0 (17.9-35.0) <0.0001
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potent inhibitor of endothelial nitric oxide production, im-
pairs vascular relaxation, contributes to hypertension, and
is correlated with CV events and renal decline [22-25].
NT-pro-BNP and troponin I are noninvasive measures of
cardiac stretch and myocyte injury, respectively, and are
known to predict CV events in diverse populations
[20,31-34]. Serum IL-6 and hsCRP are key markers of the
chronic inflammation, an important mechanism of vascu-
lar and renal disease progression [17-20,27-30]. TGFβ1 is
a key mediator of fibrosis within the kidney and other or-
gans [21,35]. Other markers of interest include cystatin C
(an alternative marker used to eGFR) [37-40], and 25-
hydroxyvitamin D (25(OH)D), as a marker of general
health and nutrition.
Baseline findings
Baseline characteristics of patients and correlates of GFR
The baseline demographics and laboratory values of the
CanPREDDICT cohort, stratified by GFR, are summa-
rized in Table 1. The mean age of the cohort at enroll-
ment was 68 years, 62% are male, and 48% diabetic.
Forty percent of the cohort was in the CKD Stage 3
(eGFR 30–45 mL/min/1.73m2) and 60% of the cohort
was in CKD Stage 4 at baseline, with 22% of the cohort
with eGFR below 20 mL/min/1.73m2. Diabetes and
hypertensive nephropathy were the most frequent pri-
mary kidney diseases (30% each), and 22% of patients
had a history of cardiac disease (CHF or IHD) at entry.
68% had either diabetes or CV disease. Compared with
patients in the higher eGFR strata, patients at lower
eGFR were slightly younger and slightly less likely to be
male. Diabetes was significantly more prevalent in the
20–29 mL/min/1.73m2 stratum than in the lower or
higher strata. At each eGFR stratum, there was a similar
distribution of those with diabetes, IHD, CHF or any
combination thereof. Of note, only 32% of the cohort0
5
10
15
20
25
30
35
40
<20ml/min 20-29ml/min >=30m
%
Figure 2 Baseline cardiovascular and diabetes comorbidities by eGFRhad neither diabetes nor CV comorbidities (Figure 2). The
expected relationship between CKD related complications
and GFR is clearly evident in the baseline analysis: abnor-
malities of Hgb, calcium, phosphate, parathyroid hormone
(PTH) and 25(OH)D were progressively more pronoun-
ced at lower GFR strata. The majority of patients were
microalbuminuric or non-proteinuric (61%); only 22%
exhibited heavy albuminuria > 1 g/day. The uACR data
is variable across strata of eGFR.
Distribution and expected values of novel biomarkers
The baseline distributions of the newer biomarkers
are illustrated in Figure 3a-g. Cystatin C and ADMA
had mound shaped, approximately normal distributions,
whereas IL-6, troponin I, hsCRP, TGFβ1 and NT-pro-BNP
exhibited marked positive skew, with the majority of mea-
surements at or below the lower limit of detection of the
assay. Of note, the median value of hsCRP was 3 mg/L,
which corresponds to the upper limit of normal in general
populations. The median, range, and proportion above the
detection limit for biomarkers with the majority of mea-
surements below the limit of detection is described in the
second part of Table 1.
The variation of biomarker levels across strata of
eGFR and uACR are presented graphically in Figure 4a-g.
The values in each cell represent the mean (cystatin C,
ADMA) or median value (NT-pro-BNP, hsCRP, TGFβ1)
for the biomarker in that cell, or the proportion of patient
results above the upper limit of detection (for IL-6, tropo-
nin I), as appropriate. Different colors indicate statistically
significant differences between cells. Such graphical repre-
sentations are useful in discerning at a glance the potential
predictive utility of a biomarker.
Discussion
CanPREDDICT represents a large cohort of CKD patients
followed by nephrologists in a single payer healthcare7 6 6
9
32
22
17
l/min Total
No Comorbidities
DM Only
DM+IschHD or CHF
IschHD Only
CHF Only
IschHD+CHF
DM+IschHD+CHF
.
Figure 3 a-g Baseline distribution of biomarkers.
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As a source of information about ‘current state’ of patients
in Canada, it is representative of that group. Better under-
standing of the outcomes of these patients will be import-
ant for healthcare planning, and for patient counseling.
Through this ongoing work development and testing ofprediction equations using additional biomarkers should
prove important.
The baseline characteristics in CanPREDDICT are
qualitatively similar to other referred CKD cohorts
[41,42], but with some important differences. By design,
CanPREDDICT had a higher representation of lower
a) Cystatin C (ng/mL), mean b) ADMA (µM), mean
c) ProBNP (pg/mL), median 
e) TGFβ1 (pg/mL), median
<30
mg/L
30-300
mg/L
300-1000
mg/L
≥1000 
mg/L
<30
mg/L
30-300
mg/L
300-1000
mg/L
≥1000 
mg/L
<30
mg/L
30-300
mg/L
300-1000
mg/L
≥1000 
mg/L
<30
mg/L
30-300
mg/L
300-1000
mg/L
≥1000 
mg/L
mL/min
mL/min
<20
mL/min
≥30 
20-29
mL/min
mL/min
<20
mL/min
≥30 
20-29
0.511 0.542 0.532 0.562
0.542 0.552 0.552 0.552
0.562 0.542 0.552 0.573
uACR
eGFR
mL/min
mL/min
<20
mL/min
≥30 
20-29
mL/min
mL/min
<20
mL/min
≥30 
20-29
mL/min
mL/min
<20
mL/min
≥30 
20-29
uACR
eGFR
<30
mg/L
30-300
mg/L
300-1000
mg/L
≥1000 
mg/L
<30
mg/L
30-300
mg/L
300-1000
mg/L
≥1000 
mg/L
<30
mg/L
30-300
mg/L
300-1000
mg/L
≥1000 
mg/L
uACR
eGFR
mL/min
mL/min
<20
mL/min
≥30 
20-29
uACR
eGFR
mL/min
mL/min
<20
mL/min
≥30 
20-29
uACR
eGFR
uACR
uACR
eGFR
g) TroponinI, % of top tertile f) IL6, % of top tertile 
21%1  34%2 41% 41%
33%2 35%2 38%2 45%3
42%2 37%2 42%2 51%3
14111 15392 15702 16903
18494 19645 20155 20285
22186 24288 23967 25008
d) hsCRP (mg/L), median 
eGFR
2.901 2.401 3.101 2.201
2.551 3.202 3.101 2.651
1.901 3.802 3.202 3.502
2371 3422 3682 4612
3812 5593 4612 7514
7124 6694 4993 12765
21,5101 20,4651 21,2601 21,8771
19,9291 19,3712 19,1712 20,5941
17,5863 18,3672 19,3452 17,6913
27%1 33%1 32%1 26%1
31%1 36%2 30%1 34%1
26%1 38%2 35%1 41%2
Figure 4 a-g Biomarker mean, median values or percentage of patients above the upper detection limit/top tertile by eGFR and uACR
level at baseline.
Levin et al. BMC Nephrology 2013, 14:121 Page 8 of 11
http://www.biomedcentral.com/1471-2369/14/121GFR strata than other similar published cohort studies
such as CRIC and CRIB [41,42]. Our cohort is also older
by a decade, has greater male predominance, but a simi-
lar proportion of diabetics. CanPREDDICT patients also
have a higher prevalence of IHD and CHF than CRIC,
findings which may relate to the aforementioned age
and eGFR differences [42]. As with CRIC, NHANES,
and AASK, the proportion of proteinuric renal diseasewas relatively low, but distributed across all strata of
eGFR [42-44]. We observe a well described relationship
between CKD related laboratory abnormalities and
eGFR [45,46]. As expected, abnormalities of Hgb, cal-
cium, phosphate, PTH and 25(OH)D were progressively
more pronounced in the lower eGFR strata. Our cohort
is also predominantly white, a finding discussed sepa-
rately under limitations below.
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with respect to future studies and potential utility in pre-
diction equations. A biomarker exhibiting a high degree
of covariation with uACR and eGFR would exhibit a
smooth “wave” of colour changing diagonally across the
table; such a biomarker would likely provide little ad-
ditional independent information to a predictive model
beyond what is already provided by measurement uACR
and eGFR, themselves strong predictors of renal disease
progression. On the other hand, a biomarker which does
not co-vary perfectly with eGFR/ACR would exhibit a
“patchwork” pattern of colours, indicating that it may be
capturing information independent of uACR and eGFR
and might therefore prove prognostically useful. Of note,
almost all biomarkers measured in the study exhibit this
patchwork pattern to some degree, suggesting these bio-
markers could add additional information to conven-
tional measures of CKD severity (via uACR and eGFR).
Our observations on these newer biomarker distribu-
tions have both practical and research applications. As
noted above, most biomarkers of inflammation and CV
disease appear right-shifted in this CKD cohort, indicat-
ing that a higher proportion of patients with CKD have
elevated values. For example, the lowest NT-pro-BNP
value in the cohort in the cell of the highest eGFR and
lowest uACR within the cohort (Figure 4c) is within the
range suggested for the diagnosis for pulmonary edema
in the general population. Caution must be used, there-
fore, in applying distribution based thresholds (i.e. “normal
ranges”) derived from the general population for clinical
decision making, as these may not be correct when ap-
plied in CKD populations. Ultimately, our objective is to
develop true risk-based thresholds, once follow-up is com-
pleted and all outcomes of interest are known.
Strengths and weaknesses
The main strength of CanPREDDICT is that it is a large,
national, prospective observational study of referred CKD
patients, with comprehensive data capture on risk factors
for progressive renal and cardiac diseases in Canada. The
dataset includes measures of six novel nontraditional bio-
markers of cardiorenal disease progression. Biobanking of
urine and blood samples will permit future genetic and
proteomic analyses. While the CanPREDDICT cohort is
qualitatively similar to other CKD cohorts, its sampling of
patients at lower eGFR and its setting in the Canadian
health system make it complementary to other national
cohorts, and provides the basis for international compa-
risons and cross-validation of findings.
The low prevalence of non-Caucasian individuals
enrolled is a relative limitation. Although the proportion
of non-white individuals in Canada is lower than in the
US, for example, non-white individuals are still under-
represented in the CanPREDDICT Cohort relative toCanadian demographics as a whole. A funding applica-
tion to extend and to enrich the cohort with non-white
individuals so that it more closely reflects Canadian
demographics is under review.
As patients were recruited at nephrology clinics across
Canada, the results of CanPREDDICT will be applicable
to CKD patients seen and followed by nephrologists
(referral cohort). This is an important group of patients
to characterize and understand, and it is expected that
the results of CanPREDDICT over time will inform
management in these patients. However, CanPREDDICT
results may not necessarily translate to CKD patients
who are not referred to nephrologists, as they are not
represented in this cohort. The logistics of identifying
and intensively following non-referred CKD patients are
considerable, and will have to be resolved in future stu-
dies. The pre-selected biomarkers, chosen for practical
reasons, did not include FGF-23, which has been shown
in multiple populations to predict CV outcomes and
death. Arrangements to measure FGF-23 in an approved
laboratory have been completed at the writing of this
paper; results are pending.
CanPREDDICT data are available for collaborations
CanPREDDICT was designed at the outset to be a plat-
form for further collaborations and studies. A 8 person
steering committee, consisting of 6 nephrologists, a stat-
istician and methodologist, and a laboratory physician
evaluates all requests, based on a predefined set of cri-
teria. To date, several sub-studies have been approved,
including one looking at bioimpedance and outcome, and
one reviewing urine protein evaluation and outcomes.
Requests for collaboration may be directed to Dr. Adeera
Levin, principal investigator and chair of the steering com-
mittee, at canpreddict@providencehealth.bc.ca.
Additional file
Additional file 1: Additional information regarding study
organization, measurement of biomarkers and sample size
calculations.
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